PrEP Implementation for HIV Prevention in Women Who Inject Drugs
What You Need to Know Before You Apply
What is the purpose of this trial?
Women who inject drugs are among the most vulnerable to acquiring HIV, but very few women who inject drugs are prescribed pre-exposure prophylaxis (PrEP) for HIV prevention largely due to barriers within our healthcare system. This research will consider the perspectives of women who inject drugs, healthcare providers, and clinic leadership to improve the way primary care and reproductive health clinics deliver PrEP to women who inject drugs, thereby reducing new HIV infections in this population.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications.
Is PrEP safe for women who inject drugs?
PrEP (Pre-Exposure Prophylaxis) is generally considered safe for preventing HIV in various populations, including people who inject drugs. However, concerns about side effects, especially with new forms like injections, have been noted, and more information may be needed to address these concerns.12345
How is the drug PrEP unique for HIV prevention in women who inject drugs?
PrEP (Pre-Exposure Prophylaxis) is unique for HIV prevention in women who inject drugs because it is specifically designed to be taken before potential exposure to HIV, offering a proactive approach to prevention. Unlike other treatments that may be used after exposure, PrEP provides a preventive measure, which is particularly important for women who face biological, behavioral, and gender-based barriers to accessing traditional HIV prevention services.23678
What data supports the effectiveness of the treatment Practice Facilitation for HIV prevention in women who inject drugs?
The research highlights that PrEP (pre-exposure prophylaxis) is effective for HIV prevention, and using coordinators to manage PrEP programs can improve access and service delivery. This suggests that structured support, like Practice Facilitation, could enhance the implementation of PrEP among women who inject drugs.2391011
Who Is on the Research Team?
Laura Starbird, PhD
Principal Investigator
University of Pennsylvania
Are You a Good Fit for This Trial?
This trial is for primary care and reproductive health clinics that have had at least 50 visits from women who inject drugs in the past year, employ a minimum of three healthcare providers, and whose leadership agrees to participate. Clinics must also have completed previous surveys.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Pre-intervention Baseline
Surveys with clinic leaders and providers on organizational capacity, readiness to change, and provider knowledge about PrEP
Intervention
Practice Facilitation intervention to improve PrEP delivery to women who inject drugs
Post-intervention Follow-up
Assessment of PrEP uptake among women who inject drugs and evaluation of intervention outcomes
What Are the Treatments Tested in This Trial?
Interventions
- Practice Facilitation
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Pennsylvania
Lead Sponsor
National Institute on Drug Abuse (NIDA)
Collaborator